ALKS
Alkermes·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 4
Bearish signal 2
Consensus Rating "Buy"
Ample Liquidity
High Gross Profit Margin
High Cash/net Profit Ratio
EPS Below Expectations
Revenue Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About ALKS
Alkermes Public Limited Company
A global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience
Connaught House, 1 Burlington Road, Dublin 4, Ireland, D04 C5Y6
--
Alkermes Public Limited Company was established in Ireland as a private limited company on May 4, 2011 under the name Antler Science Two Limited (Registration No. 498284). The company is a fully integrated global biopharmaceutical company that leverages its scientific expertise and proprietary technology to develop innovative medicines that improve patient outcomes. The Company has a diversified product portfolio including more than 20 commercial drug products and a large number of clinical candidates for the treatment of central nervous system diseases such as addiction, schizophrenia and depression.
Earnings Call
Q1/2025
Estimate EPS0.24
Actual EPS0.13
Estimate Revenue304.11M
Actual Revenue306.50M
Alkermes Q1 2025: Key Contradictions in Orexin Safety, LYBALVI Sales, and VIVITROL Funding
May 13,2025 04:39
Earnings Decrypt
Earnings Decrypt
Q2/2025
Estimate EPS0.38
Actual EPS0.52
Estimate Revenue341.30M
Actual Revenue390.66M
Alkermes Q2 2025: Unpacking Contradictions in Phase 3 Designs, Data Interpretations, and Dosing Strategies
Jul 29,2025 02:59
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
ALKS has released its 2025 Q3 earnings. EPS was reported at 0.49, versus the expected 0.39, beating expectations. The chart below visualizes how ALKS has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
ALKS has released its 2025 Q3 earnings report, with revenue of 394.19M, reflecting a YoY change of 4.24%, and net profit of 82.76M, showing a YoY change of -10.41%. The Sankey diagram below clearly presents ALKS's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
